Patents - Celltrion v Genentech
Omalizumab structure Authors Manav Segal, Jeffrey R Stokes, Thomas B. Casale Licence CC BY 2,5 Source Wikimedia Commons Jane Lambert Patents Court (HH Judge Hacon) Celltrion Inc v Genentech, Inc and another [2025] EWHC 174 (Pat) (30 Jan 2025) This was an action by Celltrion Inc ("Celltrion") for the revocation of European patent (UK) 3 805 248 B1 for a "Process for concentration of antibodies and therapeutic products thereof" ("the patent") held by Genentech Inc ("Genentech") and Novartis AG ("Novartis") and a counterclaim by Genentech and Novartis against Celltrion and its UK subsidiary for infringement. The action and counterclaim were tried by His Honour Judge Hacon between 24 Oct 2024 and 1 Nov 2024. The learned judge delivered judgment on 30 Jan 2025 (see Celltrion Inc v Genentech, Inc and another [2025] EWHC 174 (Pat) (30 Jan 2025)). By para [193] of his judgment, he found that the patent was valid and infringed. Th...